RxDoctor Payments Data

Cassie Guste

Family · Robert, LANPI 1063813681

Payments from drug & device makers

$11,622in general payments, 2019–2025

Across 581 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$896
  • Bayer$841
  • GSK$831
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$11,43898%
  • Education$1842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,622 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,899
Medicare patients
63
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$54,342
OzempicSemaglutide17$19,936
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,406
AbrysvoRsv Vacc, Pref A And Pref B/Pf15$4,905
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,593
SynthroidLevothyroxine Sodium20$1,994
Pravastatin Sodium62$1,003
Albuterol Sulfate HfaAlbuterol Sulfate19$670
Rosuvastatin Calcium23$663
Bupropion XlBupropion Hcl20$484
Levothyroxine Sodium59$420
Metoprolol Succinate19$403
Pantoprazole Sodium29$383
Atorvastatin Calcium42$330
Escitalopram Oxalate21$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$896$54,34237 claims
Novo NordiskOzempic$1,099$19,93617 claims
AstraZenecaBreztri Aerosphere$2,411$7,40612 claims
PfizerAbrysvo$642$4,90515 claims
GSKShingrix$831$3,59316 claims
AbbVieSynthroid$1,349$1,99420 claims
Almatica Pharma LLCSertraline Hcl$57$8412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Robert

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →